#USA #AbbVie #North Chicago #CLL #venetoclax

AbbVie Presenting New Insights at EHA 2026 Congress

AbbVie, a leading biopharmaceutical company, recently disclosed significant findings from a Phase 3 clinical trial regarding its venetoclax-based therapy at the European Hematology Association (EHA) 2026 Congress held in Stockholm, Sweden. This congress, which ran from June 11-14, showcased groundbreaking research in treating chronic lymphocytic leukemia (CLL).

The noteworthy data shared on the venetoclax combined regimen came from the CLL14 trial, a collaborative effort with the German CLL Study Group. As claimed by Dr. Daejin Abidoye, AbbVie’s Vice President and Therapeutic Area Head for Oncology, the nine-year follow-up results from the CLL14 trial strongly reinforce the long-term safety and efficacy of this treatment approach. These results provide substantial support for utilizing venetoclax-based regimens in first-line therapy for a wider demographic of CLL patients. Patients undergoing a fixed-duration treatment have experienced unprecedented durations of time away from subsequent therapies, effectively enhancing their quality of life.

Dr. Kirsten Fischer, one of the leading investigators in the CLL14 study, highlighted that the combination of venetoclax with obinutuzumab has shown significant improvements in treatment response rates, exhibiting extended progression-free survival in patients who have never undergone treatment previously. Notably, these patients experienced a median time to next treatment nearing eight years, indicating a remarkable durability for the combination therapy and a considerable duration devoid of CLL-specific treatment.

The rigorous follow-up over a medium of 9.2 years confirmed that venetoclax paired with obinutuzumab outperformed the alternative regimen of obinutuzumab with chlorambucil. The analysis showed a median progression-free survival (PFS) of 6.4 years for the venetoclax group compared to 3.2 years for the chlorambucil group, with significant statistical validation (HR 0.50, 95% CI 0.39-0.63, p<0.001).

While the results are promising, it's relevant to acknowledge the adverse effects tied to venetoclax therapy. The most frequently observed severe adverse events included neutropenia, thrombocytopenia, and anemia. However, the overall safety profile remained acceptable over the nine years of data collection, emphasizing a suitable tolerance by patients throughout the treatment course.

CLL remains one of the prevalent types of leukemia affecting adults, characterized by a gradual accumulation of dysfunctional B-cell lymphocytes. Patients may face relapsed or refractory conditions, which pose long-term management challenges despite advancements in treatment options. Recent studies suggest that while therapies have improved, many individuals still endure extended treatment courses, underscoring the necessity for continual research and development in this field.

About the CLL14 Phase 3 Trial

The CLL14 trial was a multicenter, randomized Phase 3 study (NCT02242942) exploring the safety and effectiveness of taking venetoclax in conjunction with obinutuzumab. The trial garnered participation from 432 patients diagnosed with previously untreated CLL who also had coexisting medical conditions. Participants were administered venetoclax for a defined timeframe of 12 months alongside six cycles of obinutuzumab, or alternatively, the standard combination of obinutuzumab and chlorambucil.

Clinical efficacy was primarily scrutinized through progression-free survival metrics, validated by an independent review committee. Secondary endpoints included rates of minimal residual disease (MRD) and overall response ratings across the patient population.

In patients receiving the venetoclax combination, adverse effects were monitored closely, particularly instances of severe neutropenia and various infections. Patients are advised continuously to evaluate their response to therapy and report any adverse reactions to their healthcare providers promptly.

About VENCLYXTO®

VENCLYXTO (venetoclax) operates as a first-in-class therapy designed to inhibit the B-cell lymphoma-2 (BCL-2) protein, a critical factor in many blood cancers that helps tumor cells evade apoptosis. This treatment thus plays a pivotal role in enhancing therapeutic potential for patients with appropriate cancers.

Commercialization of the product is a cooperative effort between AbbVie and Roche, making it available in over 80 countries, including the United States. The treatment modalities vary, indicating potential uses in conjunction with other therapies to enhance overall effectiveness in combating different types of blood cancers.

AbbVie remains committed to pioneering research efforts to explore and expand therapeutic avenues in oncology, consistently striving towards improved patient outcomes for those suffering from hard-to-treat cancers. By fostering innovation and proactive approaches, AbbVie seeks to transform the healthcare landscape for cancer patients globally.